What if the future of longevity is less about living longer and more about living better? In the latest episode of Let’s Talk Future, Jane Ross speaks with Jay Olson, CFA, Managing Director and Senior Analyst covering Biotechnology at Oppenheimer, about the biotech innovations shaping healthy aging. The conversation explores GLP-1 obesity drugs, preventive medicine, muscle preservation, inflammation, diagnostics, and personalized therapies — and how these developments could help redefine health span.<br>© 2026 Oppenheimer &amp; Co. Inc. Transacts Business on All Principal US Exchanges and is a Member of SIPC. 8942277.1

The Next Wave of Healthy Aging

Let’s Talk Future™ - An Oppenheimer Podcast

And welcome back to Let’s Talk Future™. I'm your host, Jay Ross, and I'm here with Jay Olson of Oppenheimer to talk about longevity. Jay's been exploring this area from a biotech perspective for quite some time. And last year, we recorded an episode that focused on whether longevity approaches are realistic and investable and what are the innovations that could result in longer health spans.

That episode garnered a lot of interest, and since that time, a lot has happened. Private equity, pharmaceutical companies, billionaires all continue to invest in longevity. And we have a lot more data and info because obesity drug uses continues to grow. So I'm looking forward to talking about all of this with you, Jay, and welcome back to Let’s Talk Future™.

Jane Ross Hi, Jay, and thank you for inviting me back. It's a real pleasure to join you and chat about this exciting topic. It's been a while since we last spoke and a lot has evolved, starting with the way we describe the key concept. Some people think of longevity as an esoteric goal that is pursued by billionaires who want to live longer. But as you indicated, our focus is more related to health span, that is living healthier, more functional, and higher quality lives to narrow the gap between our health span and our lifespan.

So we prefer to describe our idea as healthy aging, which seems to resonate better with all parties involved, including healthcare systems and investors. And it sounds very simple, health spans, improving health spans. And before we get into some of your more, you know, scientific stuff, what are some of the low-tech things that our listeners should be taking advantage of now?

The Next Wave of Healthy Aging

Read the full transcript

The candid version is on a podcast,
not the earnings call.

The Next Wave of Healthy Aging

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.